Positron Acquires License to Coronary Disease Program
Posted on: Wednesday, 2 July 2008, 09:01 CDT
Positron has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by Lance Gould and the University of Texas Health Science Center at Houston.
Joe Oliverio, president of Positron, said: "We are grateful to the University of Texas Health Science Center at Houston and Dr Gould for selecting Positron as the exclusive licensee of their heart disease management product.
"The market is void of such a product and will position Positron to be able to offer a total cardiac solution to customers reaching well beyond the sale to physicians."
Source: Datamonitor
Related Articles
- FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
- Positron Introduces New Attrius(TM) Cardiac PET Scanner at the Annual Meeting of the American Society of Nuclear Cardiology
- Positron Displays PULSE CDC(TM) and Introduces New Cardiac PET Scanner at the Annual Meeting of the American Society of Nuclear Cardiology
- Positron Announces Study That Suggests Cardiac PET May Help Reduce Use of Angiograms and Bypass Surgery While Reducing Costs
- Positron Acquires IS2 Medical Systems, a Nuclear Imaging Device Manufacturer
- Positron Announces Latin America Distributorship With Mayerick Corporation of Mexico
- Quantitative Software System Sets Positron As the Leader in Diagnostic and Management Needs for Coronary Artery Disease
- Positron PET Device Approved in Canada
- Imagin Molecular Corporation Announces Conversion of Positron Convertible Promissory Notes into 70 Million Shares
- Imagin Nuclear Partners Purchases Positron Emission Tomography Camera and Commences Patient Scans
Rating: 3.0 / 5 (10 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds